Real-world study of patients with HR+/ HER2- metastatic breast cancer treated with palbociclib and fulvestrant.

ABSTRACT:

Aims

To investigate real-world treatment patterns and outcomes among patients with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) who initiated first-line palbociclib-fulvestrant.

Patients & methods

Retrospective observational study of iKnowMed electronic health records among patients who initiated first-line palbociclib-fulvestrant between 1 February 2016 and 31 December 2019 and were followed through 30 June 2020. Demographic, clinical, and treatment characteristics were evaluated descriptively. Endpoints including real-world progression-free survival, overall survival, time to chemotherapy, real-world duration of therapy, and time to next treatment were assessed using Kaplan-Meier methods from first-line treat

SUBMITTER: Robert N 

PROVIDER: S-EPMC11759524 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature